3-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Completed

• Conditions: Pertussis
• Interventions: Biological: Pertagen (aP BioNet); Biological: Boostagen (TDaP BioNet); Biological: Adacel

• Registration Number: NCT04102137
• Lead Sponsor: Mahidol University

Brief Summary

In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy subjects aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th;Study ID:TCTR20150703002). A total of 450 subjects were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 subjects enrolled at each study site. During the study, the subjects had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines.

This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of subjects who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects).

In this current study, the long-term persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-detoxified Tdap vaccine (Adacel) at 3 years after previously immunized in the TDA202 study.

Detailed Description

The study population will included all subjects who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok.

The subjects who had received a single dose of one of the 3 study vaccines and completed 1-year follow-up visit at Day 336±28 during the TDA202 study will be called in for consent process at 3 years after vaccination based on Vaccination Date in TDA202 study within ±1 month window period. Subjects aged ≥ 18 years who have signed the written informed consent form or subjects aged \< 18 years who have signed the assent form with their parent/legal guardian's given written informed consent will be screened for general health status and those who fulfill all inclusion and exclusion criteria will be enrolled into the study.

Once enrolled, blood sample (approximately 5 mL) will be taken from all subjects. After blood collection, vaccination with a licensed influenza vaccine will be offered to all subjects.Blood samples will be processed for serum separation and shipped to Bionet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against tetanus (TT), diphtheria(DT), Pertussis Toxin (PT) and Filamentous hemagglutinin (FHA) and PT neutralizing antibody by Chinese Hamster Ovary (CHO cell assay) will be performed . ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled subjects while CHO cell assay to detect PT neutralizing antibody will be performed only in the same subset of 75 subjects (25 subjects in each vaccine group) who had been selected for PT neutralizing antibody assessment in the previous TDA202 study.

The knowledge from this long-term 3-year antibody persistence study will provide supportive data to identify the best alternative acellular pertussis vaccines to conventional chemically-detoxified vaccines for controlling the resurgence of pertussis disease.

Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-06-26
• Primary Completion: 2018-07-31
• Study Completion: 2018-08-27
• Status Verified: 2019-09
• Study First Submitted: 2019-09-22
• Study First Submitted QC: 2019-09-23
• Study First Posted: 2019-09-25
• Last Update Submitted: 2019-09-27
• Last Update Posted: 2019-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 181

Inclusion Criteria

1. Having participated in TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1 year follow-up visit.
2. Written informed consent is obtained for subjects aged ≥18 years, or written assent and written informed consent are obtained from subjects aged <18 years and from their parent/legal guardian, respectively, prior to study entry.
3. Capable to comply with study procedures and willing to provide with a blood sample.

Read More

Exclusion Criteria

No exclusion criteria for this study. Subjects will be eligible for participation if all inclusion criteria are met.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
3	Pertagen (aP BioNet)	Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
3	Boostagen (TDaP BioNet)	Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
3	Adacel	Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines

Primary Outcome Measures

Name	Time	Method
Comparison of anti-Diphtheria GMTs (IU/mL) between Day 336 and 3 years after vaccination	3 years after vaccination ± 1 month	Assessed by ELISA in all evaluable subjects by vaccine groups
Comparison of anti-PT GMTs (IU/mL) between baseline and 3 years after vaccination	3 years after vaccination ± 1 month	Assessed by ELISA in all evaluable subjects by vaccine groups
Comparison of anti-Tetanus GMTs (IU/mL) between Day 336 and 3 years after vaccination	3 years after vaccination ± 1 month	Assessed by ELISA in all evaluable subjects by vaccine groups
Seroconversion rates of subjects with ≥ 4-fold increase in anti-FHA antibody titers at 3 years after vaccination compared to baseline, Day 336 and 2 years after vaccination in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	by ELISA in all evaluable groups
Comparison of anti-FHA GMTs (IU/mL) between baseline and 3 years after vaccination	3 years after vaccination ± 1 month	Assessed by ELISA in all evaluable subjects by vaccine groups
Seroconversion rates of subjects with ≥ 2-fold increase in anti-PT antibody titers at 3 years after vaccination compared to baseline, Day 336 and 2 years after vaccination in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	by ELISA in all evaluable groups
Seroconversion rates of PT neutralizing antibody increase ≥ 4-fold at 3 years after vaccination compared to baseline, Day 336 and 2 years after vaccination	3 years after vaccination ± 1 month	PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group
Seroconversion rates of subjects with anti-PT antibody titers at 3 years after vaccination compared to baseline in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	Booster response: * In initially seronegative subjects (baseline titer \< 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and \< 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Seroconversion rates of subjects with ≥ 4-fold increase in anti-PT antibody titers at 3 years after vaccination compared to baseline, Day 336 and 2 years after vaccination in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	by ELISA in all evaluable groups
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Tetanus at baseline and 3 years after vaccination compared to baseline in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	Assessed by ELISA
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Diphtheria at baseline and 3 years after vaccination compared to baseline in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	Assessed by ELISA
Seroconversion rates of subjects with anti-FHA antibody titers at 3 years after vaccination compared to baseline in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	Booster response: * In initially seronegative subjects (baseline titer \< 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and \< 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Seroconversion rates of subjects with ≥ 2-fold increase in anti-FHA antibody titers at 3 years after vaccination compared to baseline, Day 336 and 2 years after vaccination in all evaluable subjects by vaccine groups	3 years after vaccination ± 1 month	by ELISA in all evaluable groups
Comparison of PT neutralizing GMTs (IU/mL) between baseline and 3 year after vaccination	3 years after vaccination ± 1 month	PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group

Trial Locations

Locations (1)

Vaccine Trial Centre, Faculty of Tropical Medicine, Mhahidol University, 420/6 Ratchawithi Road, Ratchathewi,; 🇹🇭 Bangkok, Thailand